SUPPLEMENTARY INFORMATION:

Due to circumstances beyond the control of the Department of Defense, the Designated Federal Officer for the Uniform Formulary Beneficiary Advisory Panel was unable to provide public notification required by 41 CFR 102-3.150(a) concerning the modification of the previously noticed meeting for April 1, 2020. Accordingly, the Advisory Committee Management Officer for the Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 15-calendar day notification requirement.

On February 26, 2020 (85 FR 11053-11054), the Department of Defense published a notice that announced an April 1, 2020 meeting of the Uniform Formulary Beneficiary Advisory Panel. On March 9, 2020 (85 FR 13636), the DoD published a notice that announced that the meeting time had changed. DoD is publishing this notice to announce that this federal advisory committee meeting has been modified to a remote access format.

Written Statements: Pursuant to 41 CFR 102-3.10, and section 10(a)(3) of FACA, interested persons or organizations may submit written statements to the Uniform Formulary Beneficiary Advisory Panel about its mission and/or the agenda to be addressed in this public meeting. Written statements should be submitted to the Uniform Formulary Beneficiary Advisory Panel's DFO. The DFO's contact information can be found in the FOR FURTHER INFORMATION CONTACT section of this notice. Written comments or statements must be received by the Uniform Formulary Beneficiary Advisory Panel's DFO at least five (5) business days prior to the meeting so they may be made available to the Uniform Formulary Beneficiary Advisory Panel for its consideration prior to the meeting. The Designated Federal Officer will review all submitted written statements and provide copies to all Uniform Formulary Beneficiary Advisory Panel members.

85 FR 17868